Results 111 to 120 of about 72,674 (159)
Some of the next articles are maybe not open access.

Not so NICE for CML

Lancet, The, 2002
Tessa L Holyoake   +2 more
exaly   +3 more sources

Hurdles Toward a Cure for CML: The CML Stem Cell

Hematology/Oncology Clinics of North America, 2011
Chronic myeloid leukemia (CML) is the first cancer in which a genetic alteration was proven to be of pathogenic significance and is considered a disease model for oncogene addiction, targeted therapy, and cancer stem cells (CSCs). The introduction of tyrosine kinase inhibitors (TKIs) resulted in dramatic improvement in response and survival for ...
Paolo, Gallipoli   +2 more
openaire   +2 more sources

Predicting response in CML

Blood, 2011
Predicting response in chronic myeloid leukemia (CML) patients who are offered tyrosine kinase inhibitor (TKI) second-line therapy is vitally important. For younger patients, allogeneic transplantation is still a therapeutic option Thus, physicians need new models to predict the outcome of their patients.
François, Guilhot, Joëlle, Guilhot
openaire   +2 more sources

Early Management of CML

Current Hematologic Malignancy Reports, 2019
The marked improvement in clinical outcomes for patients with chronic myeloid leukaemia (CML) can be solely attributed to the introduction of targeted therapies against the fusion oncoprotein, BCR-ABL1. However, patient responses, although generally positive, remain heterogenous.
Shanmuganathan, N., Hughes, T.P.
openaire   +3 more sources

Studies on the Specificity of CML Report from a CML‐Workshop

Tissue Antigens, 1978
In a collaboratory study involving eight different laboratories 30 human, mixed lymphocyte culture educated cytotoxic/ymphocytes (CTLs) were identified yielding reproducible cytolysis on allogenic lymphocyte target cells without detectable HLA—A, B (and C) antigenic sharing between stimulator and target cells.These CTLs were collected in one laboratory
openaire   +2 more sources

Imatinib resistance in CML

Cancer Letters, 2009
Imatinib is, at present, the first-choice treatment for patients with chronic myeloid leukaemia in chronic phase. Despite the impressive rate of complete haematological response and complete cytogenetical remissions, some cases show primary resistance or relapse after an initial response (secondary or acquired resistance).
VOLPE, Gisella   +3 more
openaire   +3 more sources

Chromosome abnormalities in CML

Baillière's Clinical Haematology, 1987
The Ph chromosome is the hallmark of CML, where it is found in more than 90% of the cases. Cytogenetically, it usually results from a t(9;22)(q34;q11). The Ph arises in a stem cell and in chronic phase is found in all haematopoietic cell lineages, although it causes only increased granulopoiesis, and sometimes increased thrombopoiesis; furthermore ...
openaire   +2 more sources

Transplantation for CML: 2010

Blood, 2010
In this issue of Blood, Saussele and colleagues from the German CML study group present data obtained from an interim safety analysis of a prospective multiarm trial in which allogeneic stem cell transplantation was used up front in selected low-risk CML patients, up front in patients presenting with advanced disease, or as planned second-line therapy ...
openaire   +2 more sources

The interferon-alpha revival in CML

Annals of Hematology, 2015
Interferon-alpha (IFNα) was once the standard of frontline treatment for chronic myeloid leukemia (CML). Its pleiotropic mechanism of action in CML includes immune activation and specific targeting of CML stem cells. Early studies of IFNα in CML demonstrated that patients in chronic phase could attain extremely stable remissions, which correlated with ...
Moshe, Talpaz   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy